Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy

NCT06953882 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

140

Enrollment

OTHER

Sponsor class

Conditions

HER2 Negative Breast Cancer

Interventions

DRUG: Ribociclib 400mg
DRUG: Letrozole 2.5mg
DRUG: Anastrazole 1mg
DRUG: Goserelin 3.6 MG
RADIATION: Adjuvant chemotherapy

Sponsor

Yale University

Collaborators

[object Object]
[object Object]